Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

8/1/24 4:05:00 PM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $CRDF alert in real time by email

SAN DIEGO, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the second quarter ended June 30, 2024 on Thursday, August 8 after the close of trading.

Conference Call and Webcast

Cardiff Oncology will host a conference call and live webcast at 4:30 p.m. ET/1:30 p.m. PT on August 8, 2024. Individuals interested in listening to the live conference call may do so by using the webcast link in the "Investors" section of the company's website at https://investors.cardiffoncology.com/news-events/events. A replay will be available in the investor relations section on the company's website following the completion of the call.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers. The Company's lead asset is onvansertib, a PLK1 inhibitor being evaluated in combination with standard of care (SoC) therapeutics in clinical programs targeting indications such as RAS-mutated metastatic colorectal cancer (mCRC), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC) and triple negative breast cancer (TNBC). These programs and the Company's broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:

James Levine

Chief Financial Officer

858-952-7670

[email protected]

Investor Contact:

Kiki Patel, PharmD

Gilmartin Group

332-895-3225

[email protected]

Media Contact:

Grace Spencer

Taft Communications

609-583-1151

[email protected]

Get the next $CRDF alert in real time by email

Recent Analyst Ratings for

$CRDF

Date	Price Target	Rating	Analyst
9/6/2024	$8.00	Buy	Craig Hallum
2/28/2022	$26.00 → $25.00	Buy	HC Wainwright & Co.
1/5/2022		Outperform	William Blair
12/8/2021	$19.00	Outperform	Robert W. Baird
12/8/2021	$19.00	Outperform	Baird
8/10/2021	$25.00 → $26.00	Buy	HC Wainwright & Co.
8/9/2021	$30.00 → $20.00	Buy	Maxim Group

More analyst ratings

Cardiff Oncology to Report Second Quarter 2024 Results and Provide Business Update

Chat with this insight

Recent Analyst Ratings for $CRDF

$CRDF Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

Pace Gary W bought $41,100 worth of shares (30,000 units at $1.37), increasing direct ownership by 4% to 697,761 units (SEC Form 4)

$CRDF Financials

Live finance-specific insights

$CRDF Leadership Updates

Live Leadership Updates

$CRDF Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

$CRDF Large Ownership Changes

This live feed shows all institutional transactions in real time.

Cardiff Oncology Reports Third Quarter 2024 Results and Provides Business Update

Cardiff Oncology Reports Second Quarter 2024 Results and Provides Business Update